Search
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.
Carfentanil
go.drugbank.com/drugs/DB01535IllicitInvestigationalVet approvedCarfentanil was first synthesized in 1974 by a team of chemists at Janssen Pharmaceutica which included Paul Janssen.
Pexidartinib
go.drugbank.com/drugs/DB12978ApprovedInvestigationalPexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor … [L7895] Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors.
Isatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigational[L12099,L12102] It is manufactured by Sanofi-Aventis U.S. under the brand name Sarclisa.[L12102] … [L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma.
Timbetasin
go.drugbank.com/drugs/DB19119InvestigationalTimbetasin is under investigation in clinical trial NCT05555589 (Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2).
AZD-1386
go.drugbank.com/drugs/DB15333InvestigationalAZD-1386 is under investigation in clinical trial NCT00945178 (Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers).
Omega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawn[A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386] … The rest of the concentration is represented by docosapentaenoic acid and traces of some other components such as alpha-tocopherol, gelatin, glycerol, sorbitol and purified water.
Safrazine
go.drugbank.com/drugs/DB09253ApprovedWithdrawnIn 1960, it was used as an antidepressant but it is now discontinued.
Alteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigational[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).
Rimtuzalcap
go.drugbank.com/drugs/DB16733InvestigationalRimtuzalcap is a novel modulator of small-conductance calcium-activated potassium channels that is under investigation for the treatment of essential tremor.